Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia

被引:41
|
作者
Koziel, H
Kim, S
Reardon, C
Li, XH
Garland, R
Pinkston, P
Kornfeld, H
机构
[1] Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Univ, Sch Med, Boston, MA 02118 USA
[4] Boston Med Ctr, Div Pulm & Crit Care, Boston, MA USA
关键词
D O I
10.1164/ajrccm.160.6.9902099
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The relationship of serum human immunodeficiency virus-1 (HIV-1) RNA levels to HIV-1 RNA levels in other compartments, such as the lungs, is not well characterized. The purpose of this study was to determine the viral burden of HIV-1 in the lungs by comparing HIV-1 RNA in cell-free bronchoalveolar lavage fluid (BALF) with that in serum. Specimens were examined from 77 HIV-seropositive adults (CD4(+) cell counts: 0 to 700 cells/mm(3); 48% receiving prescribed antiretroviral agents), comprising 43 asymptomatic individuals who were compared with 34 persons with active lung disease caused by Pneumocystis carinii (n = 26), bacteria (n = 3), Mycobacterium avium complex (n = 2), Nocardia sp. (n = 1), Aspergillus sp. (n = 1), or pulmonary Kaposi's sarcoma (n = 1). For serum HIV-1 RNA, the proportion of subjects with detectable levels and the mean values were similar for asymptomatic individuals and persons with active lung disease (85% versus 86%, respectively) (6.64 x 10(4) versus 1.81 x 10(5) HIV-1 RNA copies/ml; p = 0.13). In contrast, HIV-1 RNA in BALF was more often detected (16% versus 62%; p = 0.001), and mean values were higher(1.04 x 10(5) versus 3.31 x 10(6) HIV-1 RNA copies/ml; p = 0.032), in subjects with active lung disease than in asymptomatic subjects, independent of early or advanced clinical stages of HIV-related disease. For both study groups, HIV-l RNA levels in BALF exceeded those in serum in 56% of cases by up to 66-fold, and did not correlate with local levels of tumor necrosis factor-alpha granulocyte-macrophage colony-stimulating factor, or interleukin-16. HIV-1 proviral DNA in cells from BALF was detected in up to 86% of subjects, more frequently in persons with advanced HIV disease (p = 0.0496), and often involved > 10% of BALF cells, but did not correlate with HIV-1 RNA detected in BALF. These data provide evidence for active HIV-1 replication in the lungs. HIV-1 replication is compartmentalized relative to serum, may be restricted, is independent of HIV-1 proviral DNA and clinical stage of HIV, and may be influenced by pulmonary disease such as P. carinii pneumonia or by other local or lung-specific factors. The lungs represent a large reservoir for HIV-1, and may present a source of persistent HIV-1 replication even during periods of apparent clinical latency of HIV-1 infection.
引用
收藏
页码:2048 / 2055
页数:8
相关论文
共 50 条
  • [41] Usual Interstitial Pneumonia in a Human Immunodeficiency Virus-infected Patient
    Cao, Mengshu
    Achcar, Rosane D.
    Chung, Jonathan H.
    Solomon, Joshua J.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2016, 352 (06): : 652 - 653
  • [42] COMPLEX ETIOLOGY OF PNEUMONIA IN INFANTS PERINATALLY INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS-1
    COHENABBO, A
    WRIGHT, PF
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (07) : 545 - 547
  • [43] Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients
    Cordero, E
    Pachón, J
    Rivero, A
    Girón, JA
    Gómez-Mateos, J
    Merino, MD
    Torres-Tortosa, M
    González-Serrano, M
    Aliaga, L
    Collado, A
    Hernández-Quero, J
    Barrera, A
    Nuño, E
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) : 461 - 465
  • [44] Pneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future Directions
    Tasaka, Sadatomo
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2015, 9 : 19 - 28
  • [45] Preventing Pneumocystis carnii pneumonia in human immunodeficiency virus-infected children: New guidelines for prophylaxis
    Grubman, S
    Simonds, RJ
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (02) : 165 - 168
  • [46] Pneumocystis jiroveci pneumonia in a human immunodeficiency virus-infected patient with cytomegalovirus co-infection
    Chen, Mei-Chen
    Yu, Wen-Liang
    Yang, Chun-Chieh
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S201 - S201
  • [47] The human immunodeficiency virus-infected traveler
    Castelli, F
    Patroni, A
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (06) : 1403 - 1408
  • [48] Polycythemia in patients infected with human immunodeficiency virus-1
    Koduri, PR
    Sherer, R
    Teter, C
    AMERICAN JOURNAL OF HEMATOLOGY, 2000, 64 (01) : 80 - 81
  • [49] Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis
    Eigenmann, C
    Flepp, M
    Bernasconi, E
    Schiffer, V
    Telenti, A
    Bucher, H
    Wagels, T
    Egger, M
    Furrer, H
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (07) : 917 - 921
  • [50] INHIBITION OF THE HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE AND HUMAN IMMUNODEFICIENCY VIRUS-1 REPLICATION BY BATHOCUPROINE DISULFONIC ACID CU1+
    DAVIS, DA
    BRANCA, AA
    PALLENBERG, AJ
    MARSCHNER, TM
    PATT, LM
    CHATLYNNE, LG
    HUMPHREY, RW
    YARCHOAN, R
    LEVINE, RL
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 322 (01) : 127 - 134